Browse Studies — Arctuva

Phase 1

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cyt…

AIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic AnemiaITP - Immune Thrombocytopenia

Estimated

~$10 – $8,750

Lakefront Biotherapeutics West LLCNCT07083960

Phase 1

A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

A Phase 1b/2a, open-label dose escalation and dose expansion study of subcutaneously (SC) administered velinotamig for the treatment of adults with relapsing a…

Immune Thrombocytopenia (ITP)Warm Autoimmune Hemolytic Anemia (WAIHA)

Estimated

~$10 – $8,750

Cullinan Therapeutics Inc.NCT07738822

Phase 1

A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleuce…

Warm Autoimmune Hemolytic Anemia (WAIHA)ITP - Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia+1 more

Estimated

~$10 – $8,750

CRISPR Therapeutics AGNCT07549698

Phase 2

A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)

The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and auto…

Chronic Immune ThrombocytopeniaAutoimmune Hemolytic Anemia

Estimated

~$10 – $8,750

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07603557